Paper40544243
Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice.
Mao R and 11 others. Alzheimers Res Ther, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice. Papers, record 40544243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40544243
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calgranulin B | Major topic |
| Cognitive Dysfunction | Major topic |
| Edaravone | Major topic |
| Alzheimer Disease | Major topic |
| Animals | |
| Mice | |
| Male | |
| Mice, Transgenic | |
| Disease Progression | |
| Hippocampus | |
| Disease Models, Animal | |
| Oxidative Stress |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82271480 | the National Natural Science Foundation of China | PubMed | ||
| 82471460 | the National Natural Science Foundation of China | PubMed | ||
| BK20230053 | the Natural Science Foundation of Jiangsu Province of China | PubMed | ||
| BK20231120 | the Natural Science Foundation of Jiangsu Province of China | PubMed | ||
| 2022ZD0211800 | the STI2030-Major Projects | PubMed | ||
| ZKX22025 | Nanjing Medical Science and Technology Development Foundation | PubMed |
Source PubMed
References68
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38040838 | Colon-targeted S100A8/A9-specific peptide systems ameliorate colitis and colitis-associated colorectal cancer in mouse models. | Acta Pharmacol Sin | 2024 | https://conductscience.org/library/papers/38040838 | PubMed |
| 2 | 37496671 | QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation. | iScience | 2023 | https://conductscience.org/library/papers/37496671 | PubMed |
| 3 | 12529407 | Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. | Mol Cell Biol | 2003 | https://conductscience.org/library/papers/12529407 | PubMed |
| 4 | 24586443 | S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model. | PLoS One | 2014 | https://conductscience.org/library/papers/24586443 | PubMed |
| 5 | 38403918 | S100A8-enriched microglia populate the brain of tau-seeded and accelerated aging mice. | Aging Cell | 2024 | https://conductscience.org/library/papers/38403918 | PubMed |
| 6 | 33950214 | PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33950214 | PubMed |
| 7 | 24240735 | The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade. | Acta Neuropathol | 2014 | https://conductscience.org/library/papers/24240735 | PubMed |
| 8 | 25969431 | Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. | Ann Rheum Dis | 2015 | https://conductscience.org/library/papers/25969431 | PubMed |
| 9 | 28687052 | Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeability. | Drug Deliv | 2017 | https://conductscience.org/library/papers/28687052 | PubMed |
| 10 | 34888686 | Neuroprotective effects of synthetic borneol and natural borneol based on the neurovascular unit against cerebral ischaemic injury. | J Pharm Pharmacol | 2022 | https://conductscience.org/library/papers/34888686 | PubMed |
| 11 | 1789684 | Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. | Ann Neurol | 1991 | https://conductscience.org/library/papers/1789684 | PubMed |
| 12 | 29653606 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Alzheimers Dement | 2018 | https://conductscience.org/library/papers/29653606 | PubMed |
| 13 | 19440546 | Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. | PLoS One | 2009 | https://conductscience.org/library/papers/19440546 | PubMed |
| 14 | 33979140 | Natural Compound from Olive Oil Inhibits S100A9 Amyloid Formation and Cytotoxicity: Implications for Preventing Alzheimer's Disease. | ACS Chem Neurosci | 2021 | https://conductscience.org/library/papers/33979140 | PubMed |
| 15 | 22457725 | MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide and induces its fibrillization. | PLoS One | 2012 | https://conductscience.org/library/papers/22457725 | PubMed |
| 16 | 12640137 | Myeloid cell function in MRP-14 (S100A9) null mice. | Mol Cell Biol | 2003 | https://conductscience.org/library/papers/12640137 | PubMed |
| 17 | 25907296 | S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. | Exp Cell Res | 2015 | https://conductscience.org/library/papers/25907296 | PubMed |
| 18 | 33913042 | Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers. | AAPS PharmSciTech | 2021 | https://conductscience.org/library/papers/33913042 | PubMed |
| 19 | 35470467 | Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice. | Fundam Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35470467 | PubMed |
| 20 | 34289882 | The informed road map to prevention of Alzheimer Disease: A call to arms. | Mol Neurodegener | 2021 | https://conductscience.org/library/papers/34289882 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42039150 | Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer's disease therapy. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42039150 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40544243
GET https://conductscience.org/api/papers/v1/40544243/references?page=2